{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:36:12Z","timestamp":1760060172504,"version":"build-2065373602"},"reference-count":10,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The concept of personalized medicine (PM) has emerged as a prominent area of research to complement conventional medical approaches, grounded in the understanding that the underlying heterogeneity of individuals at the molecular, physiological, environmental exposure, and behavioral levels must be addressed by implementing interventions that are tailored or \u2018personalized\u2019 to these unique and nuanced characteristics [...]<\/jats:p>","DOI":"10.3390\/cancers17162607","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:41:53Z","timestamp":1754653313000},"page":"2607","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Issue \u2018\u2019Pre-Clinical Studies of Personalized Medicine for Cancer Research\u2019\u2019"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mechahougui, H., Gutmans, J., Colarusso, G., Gouasmi, R., and Friedlaender, A. (2024). Advances in Personalized Oncology. Cancers, 16.","DOI":"10.3390\/cancers16162862"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Esposito, A., Crimini, E., Criscitiello, C., Belli, C., Scafetta, R., Scalia, R., Castellano, G., Giordano, E., Katrini, J., and Ascione, L. (2024). The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit. Cancers, 16.","DOI":"10.3390\/cancers16244252"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ramos, R., Moura, C.S., Costa, M., Lamas, N.J., Correia, R., Garcez, D., Pereira, J.M., Lindahl, T., Sousa, C., and Vale, N. (2025). Lung Cancer Therapy: The Role of Personalized Medicine. Cancers, 17.","DOI":"10.3390\/cancers17050725"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hutyra-Gram \u00d6tv\u00f6s, R., Krynska, H., Gudoityte, G., Skribek, M., Oniscu, A., Berkovska, O., Strau\u00df, K., Zipprick, J., Tamborero, D., and Alexeyenko, A. (2025). Ex Vivo Drug Sensitivity of Pleural Effusion-Derived Cells from Lung Cancer and Pleural Mesothelioma Patients Is Linked to Clinical Response. Cancers, 17.","DOI":"10.3390\/cancers17142363"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rodgers, L.T., Villano, J.L., Hartz, A.M.S., and Bauer, B. (2024). Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models. Cancers, 16.","DOI":"10.20944\/preprints202406.1373.v1"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rodgers, L.T., Maloney, B.J., Hartz, A.M.S., and Bauer, B. (2025). Fluorescence-Guided Resection of GL261 Red-FLuc and TRP-MCherry-FLuc Mouse Glioblastoma Tumors. Cancers, 17.","DOI":"10.3390\/cancers17050734"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yang, Y., Zhou, Y., Wang, J., Zhou, Y., Watowich, S.S., and Kleinerman, E.S. (2024). CD103+ CDC1 Dendritic Cell Vaccine Therapy for Osteosarcoma Lung Metastases. Cancers, 16.","DOI":"10.3390\/cancers16193251"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Springer, C., Humayun, D., and Skouta, R. (2024). Cuproptosis: Unraveling the Mechanisms of Copper-Induced Cell Death and Its Implication in Cancer Therapy. Cancers, 16.","DOI":"10.3390\/cancers16030647"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jabbari, P., Yazdanpanah, O., Benjamin, D.J., and Rezazadeh Kalebasty, A. (2024). Supplement Use and Increased Risks of Cancer: Unveiling the Other Side of the Coin. Cancers, 16.","DOI":"10.3390\/cancers16050880"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Muranaka, H., Akinsola, R., Billet, S., Pandol, S.J., Hendifar, A.E., Bhowmick, N.A., and Gong, J. (2024). Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention. Cancers, 16.","DOI":"10.3390\/cancers16051057"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2607\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:26Z","timestamp":1760034386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":10,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17162607"],"URL":"https:\/\/doi.org\/10.3390\/cancers17162607","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,8,8]]}}}